Wedbush Sticks to Its Buy Rating for Albireo Pharma Inc (ALBO)

By Ryan Adsit

In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on Albireo Pharma Inc (NASDAQ: ALBO), with a price target of $69. The company’s shares opened today at $28.93.

According to TipRanks.com, Moussatos is ranked 0 out of 5 stars with an average return of -3.7% and a 38.4% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Allena Pharmaceuticals Inc, Aquestive Therapeutics Inc, and Catabasis Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Albireo Pharma Inc with a $69 average price target.

See today’s analyst top recommended stocks >>

Based on Albireo Pharma Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $14.6 million. In comparison, last year the company had a GAAP net loss of $6.51 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Albireo Pharma, Inc. is a pharmaceutical company, which engages in the development and commercialization of bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its product pipeline includes A4250, Elobixibat, and A3384.